Hera Diagnostics develops portable diagnostic devices utilizing optical and electrical spectroscopy combined with artificial intelligence to enable immediate cancer screening for cervical, skin, throat, and stomach cancers. These tools provide real-time results and eliminate the need for biopsies, improving access to essential healthcare services for patients in remote areas and underserved communities.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer screening methods often rely on biopsies and laboratory analysis, leading to delays in diagnosis and treatment. Access to these services can be limited, particularly for individuals in remote areas or underserved communities.
Solution
Hera Diagnostics is developing portable diagnostic devices that utilize optical and electrical spectroscopy combined with artificial intelligence to enable immediate cancer screening. These devices aim to provide real-time results, potentially eliminating the need for traditional biopsies in certain screening scenarios. The company's focus is on improving access to essential healthcare services, particularly for women's health, by modernizing cervical cancer screenings. The technology combines spectroscopy with AI algorithms to analyze samples and provide rapid diagnostic information.
Target Audience
The primary target audience includes healthcare providers in remote areas, underserved communities, and settings where rapid cancer screening is needed, with an initial focus on women's health services.
Features
- Portable diagnostic devices for point-of-care cancer screening.
- Utilizes optical and electrical spectroscopy for sample analysis.
- Employs artificial intelligence algorithms for real-time results.
- Focus on cervical cancer screening as an initial application.
- Aims to reduce the need for traditional biopsies.